抗體的生物素化標(biāo)記實驗要點：

1. 磷酸化血小板源性生長因子受體B抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；

8.在細(xì)胞的熒光標(biāo)記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。

產(chǎn)品訂購信息：
英文名稱  Anti-Phospho-PDGF Receptor beta (Tyr716) 

中文名稱   磷酸化血小板源性生長因子受體B抗體規(guī)格 

別    名  PDGFRB(phospho Y716); PDGF Receptor beta (phospho Y716); PDGF Receptor beta (phospho Tyr716); Beta platelet derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD 140B; CD140 antigen-like family member B; CD140B; CD140B; CD140b antigen; JTK12; OTTHUMP00000160528; PDGF R beta; PDGF-R-beta; PDGFR 1; PDGFR; PDGFR beta; PDGFR1; PDGFRB; PGFRB_HUMAN; Platelet derived growth factor receptor 1; Platelet derived growth factor receptor beta; Platelet derived growth factor receptor beta; polypeptide.

濃    度   1mg/1ml

規(guī) 格  0.1ml/100μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog, Pig, Cow, Rabbit 

產(chǎn)品類型   一抗 磷酸化抗體  

研究領(lǐng)域     免疫學(xué) 信號轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 細(xì)胞膜受體

蛋白分子量  predicted molecular weight: 190kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human PDGFRB around the phosphorylation site of Tyr716 [EL(p-Y)SN] 

亞    型   IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化血小板源性生長因子受體B抗體規(guī)格 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. This gene is flanked on chromosome 5 by the genes for granulocyte-macrophage colony-stimulating factor and macrophage-colony stimulating factor receptor; all three genes may be implicated in the 5-q syndrome. A translocation between chromosomes 5 and 12, that fuses this gene to that of the translocation, ETV6, leukemia gene, results in chronic myeloproliferative disorder with eosinophilia. [provided by RefSeq].

Function : Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor.

Subunit : Interacts with homodimeric PDGFB and PDGFD, and with heterodimers formed by PDGFA and PDGFB. May also interact with homodimeric PDGFC. Monomer in the absence of bound ligand. Interaction with homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD, leads to receptor dimerization, where both PDGFRA homodimers and heterodimers with PDGFRB are observed. Interacts with SH2B2/APS. Interacts directly (tyrosine phosphorylated) with SHB. Interacts (tyrosine phosphorylated) with PIK3R1. Interacts (tyrosine phosphorylated) with CBL. Interacts (tyrosine phosphorylated) with SRC and SRC family kinases. Interacts (tyrosine phosphorylated) with PIK3C2B, maybe indirectly. Interacts (tyrosine phosphorylated) with SHC1, GRB7, GRB10 and NCK1. Interaction with GRB2 is mediated by SHC1. Interacts (via C-terminus) with SLC9A3R1.

Subcellular Location : Cell membrane; Single-pass type I membrane protein. Cytoplasmic vesicle. Lysosome lumen. Note=After ligand binding, the autophosphorylated receptor is ubiquitinated and internalized, leading to its degradation

N-glycosylated.

Ubiquitinated. After autophosphorylation, the receptor is polyubiquitinated, leading to its degradation.

DISEASE : Note=A chromosomal aberration involving PDGFRB is found in a form of chronic myelomonocytic leukemia (CMML). Translocation t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal clonal myeloid proliferation and by progression to acute myelogenous leukemia (AML).

Note=A chromosomal aberration involving PDGFRB may be a cause of acute myelogenous leukemia. Translocation t(5;14)(q33;q32) with TRIP11. The fusion protein may be involved in clonal evolution of leukemia and eosinophilia.

Note=A chromosomal aberration involving PDGFRB may be a cause of juvenile myelomonocytic leukemia. Translocation t(5;17)(q33;p11.2) with SPECC1.

Defects in PDGFRB are a cause of myeloproliferative disorder chronic with eosinophilia (MPE) [MIM:131440]. A hematologic disorder characterized by malignant eosinophils proliferation. Note=A chromosomal aberration involving PDGFRB is found in many instances of myeloproliferative disorder chronic with eosinophilia. Translocation t(5;12) with ETV6 on chromosome 12 creating an PDGFRB-ETV6 fusion protein. Translocation t(5;15)(q33;q22) with TP53BP1 creating a PDGFRB-TP53BP1 fusion protein.

Note=A chromosomal aberration involving PDGFRB may be the cause of a myeloproliferative disorder (MBD) associated with eosinophilia. Translocation t(1;5)(q23;q33) that forms a PDE4DIP-PDGFRB fusion protein.

Note=A chromosomal aberration involving PGFRB is found in a patient with T-lymphoblastic lymphoma (T-ALL) and an associated myeloproliferative neoplasm (MPN) with eosinophilia. Translocation t(5;6)(q33-34;q23) with CEP85L. The translocation fuses the 5'-end of CEP85L (isoform 4) to the 3'-end of PDGFRB.

Similarity : Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.

Contains 5 Ig-like C2-type (immunoglobulin-like) domains.

Contains 1 protein kinase domain.

Database links : UniProtKB/Swiss-Prot: P09619.1

抗體的鑒定：

1）磷酸化血小板源性生長因子受體B抗體規(guī)格 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。

Human Beta anti-galactan proteins IgG ELISA Kit 人β乳糖蛋白抗體IgGMulti-class antibodies規(guī)格： 48T

Anti-IL-3 白介素3抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh LRIG2 LRIG2抗體 規(guī)格 0.2ml

SPA(Human Staphylococal protein A) ELISA Kit 人葡萄球菌蛋白A 96T

phospho-RAD9(Ser387) 英文名稱： 磷酸化細(xì)胞周期檢查控制蛋白質(zhì)抗體 0.1ml

Clenbuterol 英文名稱： 克侖特羅/抗體 0.1ml

Anti-IL-3 白介素3抗體Multi-class antibodies規(guī)格： 0.1ml

Anti-LIMK1 /FITC 熒光素標(biāo)記單絲氨酸蛋白激酶1抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-STK/CK II Alpha/FITC 熒光素標(biāo)記屬絲/蘇氨酸蛋白質(zhì)激酶抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh Adropin 能量平衡相關(guān)蛋白抗體 規(guī)格 0.2ml

Rabbit Anti-Goat IgM/APC APC標(biāo)記的兔抗羊IgM 0.1ml

GABA A Receptor beta 2 + 3 英文名稱： G基受體β2+3/GABAA Rβ2+GABAA Rβ2抗體 0.2ml

Rhesus antibody Rh Rabbit Anti-dog IgG/Cy3 Cy3標(biāo)記的兔抗狗IgG 規(guī)格 0.1ml

Anti-STK/CK II Alpha/FITC 熒光素標(biāo)記屬絲/蘇氨酸蛋白質(zhì)激酶抗體IgGMulti-class antibodies規(guī)格： 0.2ml

BDNF 小鼠腦衍化神經(jīng)營養(yǎng)因子Multi-class antibodies規(guī)格： 48T

Anti-FDC-SP/ADC 濾泡樹突細(xì)胞分泌蛋白抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh Mouse Anti-rat IgG/Alexa Fluor 350 Alexa Fluor 350標(biāo)記的小鼠抗大鼠IgG 規(guī)格 0.1ml

EMA(Human Epithelial membrane antigen) ELISA Kit 人上皮膜抗原 96T

SLAP2 英文名稱： SLAP2抗體 0.1ml

C4orf27 英文名稱： 4號染色體開放閱讀框27抗體 0.2ml

Anti-FDC-SP/ADC 濾泡樹突細(xì)胞分泌蛋白抗體Multi-class antibodies規(guī)格： 0.2ml

MannitolSaltAgarMedium

DG-18瓊脂基礎(chǔ) 250(g) incubation media DG-18瓊脂基礎(chǔ) 250(g)

Aliz-gal瓊脂 100g 用于大腸菌群平板計數(shù)的快速檢測

多粘菌素B用培養(yǎng)基多粘菌素B效價測定

LactoseSulfiteMedium(LS)

孟加拉紅培養(yǎng)基(虎紅培養(yǎng)基)250g用于食品中霉菌及酵母菌總數(shù)測定

麥康凱肌醇阿東醇青霉素瓊脂基礎(chǔ)(MIAC) 100(g) incubation media 麥康凱肌醇阿東醇青霉素瓊脂基礎(chǔ)(MIAC) 100(g)

PDP瓊脂 King Medium A 250克 綠膿菌色素測定

胰酪胨大豆羊血瓊脂基礎(chǔ)250用于蠟樣芽孢桿菌的溶血測試驗(SN標(biāo)準(zhǔn))incubationmedia胰酪胨大豆羊血瓊脂基礎(chǔ)250用于蠟樣芽孢桿菌的溶血測試驗(SN標(biāo)準(zhǔn))

T1N1Agar

磷酸化血小板源性生長因子受體B抗體規(guī)格 新生霉素(改良E.C新生霉素增菌肉湯凍干配套試劑)  規(guī)格：  4.5mg/支x10  用途：  每支添加于225ml（028112）中配成改良E.C新生霉素增菌肉湯。

改良麥康凱肉湯凍干配套試劑  規(guī)格：  10支  用途：  每支添加于100ml（025106）或(025108)中

亞碲酸(山梨醇麥康凱培養(yǎng)基凍干配套試劑)  規(guī)格：  1.25mg/支x10  用途：  每支添加于500ml（025102）中配成山梨醇麥康凱培養(yǎng)基。

頭孢磺啶(MUGal肉湯凍干配套試劑)  規(guī)格：  0.5mg/支x10  用途：  每支添加于100ml（022051）中配成MUGal肉湯。